| Cell line name |
BT-474 Tam2 |
|---|
| Accession |
CVCL_A4AK |
|---|
| Resource Identification Initiative |
To cite this cell line use: BT-474 Tam2 (RRID:CVCL_A4AK) |
|---|
| Comments |
Population: Caucasian.
Doubling time: ~2 weeks (ATCC=CRL-3434).
Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
Omics: Deep exome analysis.
Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
|---|
| Sequence variations |
- Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
- Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
- Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
- Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
- Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
- Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Invasive breast carcinoma of no special type (NCIt: C4194) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0179 (BT-474) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
60Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=27378269; DOI=10.1186/s12885-016-2452-5; PMCID=PMC4932681
Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P., Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
BMC Cancer 16:378.1-378.17(2016) |
|---|
| Cross-references |
|---|
| Cell line collections (Providers) |
ATCC; CRL-3434
|
|---|
| Cell line databases/resources |
cancercelllines; CVCL_A4AK
|
|---|
| Encyclopedic resources |
Wikidata; Q105506552
|
|---|
| Entry history |
|---|
| Entry creation | 12-Jan-2021 |
|---|
| Last entry update | 02-May-2024 |
|---|
| Version number | 6 |
|---|
